• We were once a nation of Coke vs. Pepsi. The stakes of the game have changed.

    Elizabeth Arvelos Coetzee/WSJ

    For decades, Diet Coke has been a durable pop culture icon, as much a symbol of boardroom swashbuckling as high fashion society. Its buzzy 1980s origins featured endorsements from celebrities including Paula Abdul, Whitney Houston and Demi Moore. More recently, limited-edition Diet Coke cans were released to coincide with “The Devil Wears Prada” sequel.

    The soda is also beloved across generations. It has been given the mantle of “fridge cigarette” by a Gen Z cohort who, according to Cosmopolitan, want to “blow off steam without the actual fumes” and is repped by quintessential baby boomers, including Bill Gates in a TikTok he posted of himself re-creating Warren Buffett’s recipe for Dusty Diet Coke. (That’s a bizarro mix of the soda, vanilla ice cream, chocolate syrup and malted milk powder.)

    Even the magic button that summons Diet Cokes to the Oval Office reappeared on the Resolute Desk last January, much to the irritation of the Secretary of Health and Human Services.

    All of this soft-drink soft power belies an uneasy truth for Diet Coke fanatics. The diet soda sweeping the nation is actually the beverage’s own sibling, Coke Zero Sugar—part of a zero-sugar soda boom that accounted for 52% of growth in soft drink sales last year, according to the market research firm Circana. Sales of Diet Coke, by comparison, have been, well, pretty flat since the soda peaked in popularity in 2006.

    In January, President Trump reinstalled a button on the Oval Office Resolute Desk (right) that summons Diet Cokes.

    In January, President Trump reinstalled a button on the Oval Office Resolute Desk (right) that summons Diet Cokes. Chip Somodevilla/Getty Images

    As Coke Zero gets bigger, and threatens to dethrone “DC” as the most important diet soda property in the Coca-Cola extended universe, the feud between Diet Coke fans and Coke Zero drinkers is getting pretty fizzy.

    Read more …

  • Diabetes 01.12.2025 No Comments

    Top Type 1 Diabetes Research Breakthroughs to Watch in 2025

    Over the last twenty years, as technology has advanced at lightning speed, the T1D community has undergone its own transformation, with digital health and cutting-edge research driving remarkable diabetes breakthroughs.

    Top Type 1 Diabetes Research Breakthroughs to Watch in 2025

    New and improved insulin pumps and continuous glucose monitors (CGMs), artificial pancreas systems, beta cell regeneration, encapsulation, bionic pump therapy—plus clinical trials happening right now that render individuals insulin independent.

    These trailblazing discoveries alone should be reason enough to commemorate this time in history and hope for even broader breakthroughs on the T1D horizon.

    Type 1 Diabetes Research in 2025

    When someone is diagnosed with type 1 diabetes, the first question they and their loved ones ask is how close are scientists to finding a cure? Since the discovery of insulin in 1921 (over 100 years ago!), diabetes treatment and technological advancements for the chronic disease have come in waves. Now, finally, the pendulum appears to be swinging with upward momentum.

    Thanks to the American Diabetes Association (ADA), Breakthrough T1D (formerly JDRF)Diabetes Research Institute and continued government funding for the Special Diabetes Program (SDP), exploration into a cure continues to grow. More specifically, treatments to reverse, slow down and aid individuals with type 1 diabetes seem to have had a resurgence of late.

    What’s more, StartUp Health’s T1D Moonshot Program offers opportunities to entrepreneurs, scientists and philanthropists to accelerate innovation toward managing the disease and finding a cure for T1D.

    T1D Advances on the Horizon

    When someone thinks of a cure – they expect the illness or disease to cease from being. There is hope for a biological cure for T1D. Ideally, concerning type 1 diabetes care, a cure requires the body to start producing its own insulin again and normalizing blood sugar levels without the added risk of immunosuppression drug side effects.

    Here are some diabetes breakthroughs to watch for – that keep improving.

    Diabetes Devices: High Tech Insulin Pump Therapy

    The Cutting Edge of Automated Insulin Delivery

    To continue reading the rest of this story, please click (HERE)

  • Big Changes Are Coming for 2026 Medicare Plans. What You Need to Know.

    Skinnier benefits, higher premiums and fewer options mean more than a million seniors should shop for new coverage during open enrollment

    Illustration of pills with dollar signs.

    Alexandra Citrin-Safadi/WSJ

    Last year, seniors picking Medicare coverage faced some tough choices. This year might be even worse.

    The enrollment period for 2026 Medicare coverage starts Wednesday, and it is likely to be a difficult one for many enrollees. For the second year in a row, big Medicare insurers are getting rid of some plans, trimming popular benefits and increasing out-of-pocket costs such as deductibles.

    The upshot: Seniors have to be careful, or they might end up with a bad surprise such as higher drug costs or the loss of a favorite doctor.

    “This year is a nightmare,” said Marcia Mantell, a retirement-planning consultant. Medicare enrollees “have to know more than they ever have had to know…it’s all the hidden stuff,” she said.

    Behind the turmoil are business realities. Medicare insurers have seen their profits squeezed by higher-than-expected medical spending and regulatory changes. Now, some of the biggest are trying to improve their margins by dumping unprofitable products and by controlling costs better.

    The moves might make their products less appealing. The industry is projecting that enrollment in private Medicare plans, known as Medicare Advantage, will shrink in 2026. That would be the first time in 15 years, according to the health researcher KFF.

    “What many of the companies have talked about is really pricing for profitability rather than for growth,” said Lisa Gill, a senior analyst at J.P. Morgan.

    Here’s what you need to know about navigating this year’s Medicare enrollment pitfalls.

    Read more …